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Introduction {#sec001}
============

Sexual reproduction relies on meiosis, the specialized cell division that generates haploid gametes, such as sperm and eggs, from diploid progenitors so that fertilization restores diploidy. To ensure that gametes inherit the correct number of chromosomes, meiotic chromosome segregation is exquisitely choreographed: Homologous chromosomes segregate in meiosis I and sister chromatids segregate in meiosis II. Having an incorrect number of chromosomes, also called aneuploidy, is associated with infertility, miscarriages and birth defects, underscoring the importance of understanding this process to human health.

Events in meiotic prophase ensure proper chromosome segregation. During prophase, homologous chromosomes undergo progressively intimate interactions that culminate in synapsis and crossover recombination (reviewed in \[[@pgen.1008904.ref001]\]). After homologs pair, a macromolecular complex, called the synaptonemal complex (SC), is assembled between them in a process called synapsis. Synapsis is a prerequisite for crossover recombination to generate the linkages, or chiasmata, between homologous chromosomes that direct meiotic chromosome segregation \[[@pgen.1008904.ref002]--[@pgen.1008904.ref008]\]. Defects in any of these events can result in chromosome missegregation during the meiotic divisions and gametes, and therefore embryos, with an incorrect number of chromosomes.

Coordinating the events of pairing, synapsis and crossover recombination is essential for their proper progression. For example, defects that uncouple pairing and synapsis can produce situations in which non-homologous chromosomes are inappropriately synapsed and unable to undergo crossover recombination. Mutations that produce non-homologous synapsis often identify mechanisms that are important for homolog pairing. For example, in maize, budding yeast and mice, where the initiation of meiotic recombination plays an integral role in promoting accurate homolog pairing and synapsis, mutations in genes involved in homologous recombination can produce non-homologous synapsis to varying degrees \[[@pgen.1008904.ref009]--[@pgen.1008904.ref017]\]. In *Drosophila* and *C*. *elegans*, two organisms in which correct pairing and synapsis can occur independent of recombination events \[[@pgen.1008904.ref018], [@pgen.1008904.ref019]\], other mechanisms ensure correct homologous synapsis, including integrity of meiotic chromosome axes \[[@pgen.1008904.ref020]--[@pgen.1008904.ref023]\], highly regulated chromosome movement \[[@pgen.1008904.ref024], [@pgen.1008904.ref025]\], centromere clustering \[[@pgen.1008904.ref026]\] and specific histone modifications \[[@pgen.1008904.ref027]\].

Despite these differences, in most organisms, the conserved AAA-ATPase PCH-2 (Pch2 in budding yeast, PCH2 in *Arabidopsis* and *Drosophila* and TRIP13 in mice) is crucial to coordinate events in meiotic prophase. *In vitro* and cytological experiments indicate that it does this by using the energy of ATP hydrolysis to remodel meiotic HORMADs \[[@pgen.1008904.ref028]--[@pgen.1008904.ref032]\], chromosomal proteins that are essential for pairing, synapsis, recombination and checkpoint function \[[@pgen.1008904.ref020]--[@pgen.1008904.ref022], [@pgen.1008904.ref033]--[@pgen.1008904.ref041]\]. HORMADs are a protein family defined by the ability of a domain, the HORMA domain, to adopt multiple conformations that specify protein function \[[@pgen.1008904.ref042]--[@pgen.1008904.ref044]\]. Meiotic HORMADs appear to adopt two conformations: a "closed" version, that forms upon binding a short peptide within other proteins \[[@pgen.1008904.ref045]\]; and a more extended, or "unlocked," version \[[@pgen.1008904.ref046]\]. The closed form of meiotic HORMADs assemble on meiotic chromosomes to drive pairing, synapsis and recombination \[[@pgen.1008904.ref045]\]. The physiological relevance of the unlocked version is unknown.

Cytological experiments in budding yeast, plants and mice show that PCH-2 removes or redistributes meiotic HORMADs on chromosomes \[[@pgen.1008904.ref028], [@pgen.1008904.ref030]--[@pgen.1008904.ref032]\]. This change in localization both contributes to and reflects the progression of meiotic prophase events \[[@pgen.1008904.ref028], [@pgen.1008904.ref030]--[@pgen.1008904.ref032]\]. However, major events in meiotic prophase, such as pairing, synapsis initiation and recombination, precede the removal or redistribution of meiotic HORMADs, raising the question of how PCH-2 affects these events to produce the phenotypes reported in its absence. Indeed, the phenotypes associated with loss of *PCH2* are inconsistent with its only role being the redistribution of meiotic HORMADs \[[@pgen.1008904.ref047]--[@pgen.1008904.ref049]\]. In *C*. *elegans*, PCH-2 regulates meiotic prophase events but not the localization of meiotic HORMADs \[[@pgen.1008904.ref050]\], indicating that 1) the removal or relocalization of meiotic HORMADs is not essential for PCH-2's effects on pairing, synapsis and recombination; and 2) this model organism is particularly relevant to better understand how PCH-2 regulates these events.

We previously showed that in the absence of PCH-2, homolog pairing, synapsis and recombination are accelerated and associated with an increase in meiotic defects, leading us to speculate that PCH-2 disassembles molecular intermediates between homologous chromosomes that underlie these events to ensure their fidelity \[[@pgen.1008904.ref050]\]. Specifically, we hypothesized that these molecular intermediates involve meiotic HORMADs and PCH-2 remodels meiotic HORMADs to proofread these homolog interactions \[[@pgen.1008904.ref050]\]. To test this model, we generated a mutant version of PCH-2 that binds ATP, and its substrates, but cannot hydrolyze ATP and therefore cannot remodel and release its substrates. We reasoned that if our hypothesis is correct, this mutant protein will "trap," and allow us to more easily visualize, inappropriate homolog interactions that are incorrectly stabilized. This is accurate: *pch-2*^*E253Q*^ mutants delay homolog pairing and accelerate synapsis, producing non-homologous synapsis. Meiotic DNA repair occurs with normal kinetics but crossover assurance is lost, suggesting that crossover-specific recombination intermediates between incorrect partners may also be inappropriately stabilized. Surprisingly, loss of CMT-1, an adapter protein that is thought to be essential for PCH-2 to bind its substrates, phenotypically resembles *pch-2*^*E253Q*^ mutants. Since PCH-2 localizes normally to meiotic chromosomes in the absence of CMT-1, these data indicate that CMT-1 is dispensable for PCH-2 to bind its meiotic substrates on chromosomes but is essential to hydrolyze ATP and remodel its substrates.

Results {#sec002}
=======

PCH-2^E253Q^ localizes normally during meiotic prophase {#sec003}
-------------------------------------------------------

We introduced a mutation by CRISPR/Cas9 genomic editing \[[@pgen.1008904.ref051], [@pgen.1008904.ref052]\] in the Walker B motif of PCH-2, E253Q, that allows it to bind ATP, but not hydrolyze it. We designated this allele *pch-2(blt5)* but will refer to it as *pch-2*^*E253Q*^ (*pch-2*^*EQ*^ in Figures). In budding yeast, this mutation abolishes PCH-2's *in vivo* meiotic function \[[@pgen.1008904.ref029]\]. *In vitro*, PCH-2^E253Q^ retains high affinity nucleotide binding, forms stable hexamers and interacts with its substrates \[[@pgen.1008904.ref053]\]. In meiotic nuclei, PCH-2^E253Q^ localized normally to meiotic chromosomes ([Fig 1A](#pgen.1008904.g001){ref-type="fig"}, grayscale images in [S4A Fig](#pgen.1008904.s004){ref-type="supplementary-material"}), appearing as foci just prior to the entry into meiosis (also known as the transition zone) and co-localizing with the synaptonemal complex once synapsis had initiated ([Fig 1B](#pgen.1008904.g001){ref-type="fig"}, grayscale images in [S4B Fig](#pgen.1008904.s004){ref-type="supplementary-material"}). It was also removed from the synaptonemal complex in late pachytene, similar to wildtype PCH-2 ([Fig 1C](#pgen.1008904.g001){ref-type="fig"}, grayscale images in [S4C Fig](#pgen.1008904.s004){ref-type="supplementary-material"}).

![PCH-2^E253Q^ localizes to meiotic chromosomes similar to wildtype PCH-2.\
A. Whole germline images of PCH-2 and DAPI staining in a wildtype and *pch-2*^*E253Q*^ mutant germline. Scale bar indicates 20 microns. Meiotic nuclei in mid-pachytene (B) and late pachytene (C) stained with DAPI and antibodies against PCH-2 in wildtype animals and *pch-2*^*E253Q*^ mutants. Unless otherwise stated, all scale bars indicate 5 microns.](pgen.1008904.g001){#pgen.1008904.g001}

*pch-2*^*E253Q*^ mutants delay pairing {#sec004}
--------------------------------------

Next, we analyzed pairing in *syp-1* mutants. SYP-1 is a component of the synaptonemal complex (SC), and *syp-1* mutants fail to assemble SC between paired homologs, allowing us to more easily visualize pairing intermediates in the absence of synapsis \[[@pgen.1008904.ref006]\]. In *C*. *elegans*, *cis*-acting sites called pairing centers (PCs) are required for pairing and synapsis \[[@pgen.1008904.ref054]\]. In the absence of synapsis, homologous chromosomes exhibit stable pairing of PC, but not non-PC, ends of chromosomes \[[@pgen.1008904.ref054]\]. We monitored synapsis-independent pairing at PC sites by performing immunofluorescence against HIM-8, which binds PCs of X chromosomes \[[@pgen.1008904.ref055]\] ([Fig 2B](#pgen.1008904.g002){ref-type="fig"}). A single focus of HIM-8 indicates paired X chromosomes while two foci indicate unpaired X chromosomes. When we imaged stained germlines, we divided germlines into six equal sized zones (see cartoon in [Fig 2A](#pgen.1008904.g002){ref-type="fig"}). Because meiotic nuclei are arranged spatiotemporally in the germline, this allows us to assess pairing as a function of meiotic progression.

![Homolog pairing is delayed in *pch-2*^*E253Q*^ mutants.\
A. Cartoon of *C*. *elegans* germline divided into six equivalent zones. B. Images of meiotic nuclei stained with DAPI and antibodies against HIM-8. C. Timecourse of X chromosome pairing in wildtype, *pch-2*^*E253Q*^ and *pch-2*Δ mutant germlines. Error bars indicate 95% confidence intervals.](pgen.1008904.g002){#pgen.1008904.g002}

*syp-1* mutants initiated pairing in zone 2, maintained pairing at the X chromosome PC in zones 3,4 and 5 and destabilized pairing in zone 6 ([Fig 2C](#pgen.1008904.g002){ref-type="fig"}). As we previously reported \[[@pgen.1008904.ref050]\], *syp-1;pch-2*Δ double mutants also initiated PC pairing in zone 2 but had significantly more nuclei with paired HIM-8 signals than *syp-1* single mutants (p value \< 0.0001, two-tailed Fisher's exact test), indicating that pairing is accelerated in this background. By contrast, *syp-1; pch-2*^*E253Q*^ double mutants had significantly fewer nuclei with paired HIM-8 signals in zone 2 than both *syp-1* single (p value \< 0.0001, two-tailed Fisher's exact test) and *syp-1;pch-2*Δ double mutants (p value \< 0.0001, two-tailed Fisher's exact test). In later zones, all three genotypes closely resembled each other in that chromosomes are paired. However, in zone 4, significantly fewer X chromosomes were paired in *syp-1; pch-2*^*E253Q*^ double mutants than *syp-1* single mutants (p value = 0.0003, two-tailed Fisher's exact test). Thus, *syp-1; pch-2*^*E253Q*^ mutants delay and exhibit defects in pairing at PCs, consistent with our model that PCH-2 proofreads homolog pairing intermediates: If *pch-2*^*E253Q*^ mutants "trap" incorrect pairing intermediates, between non-homologous chromosomes, for example, this would affect pairing between homologous chromosomes.

*pch-2*^*E253Q*^ mutants accelerate synapsis and produce non-homologous synapsis {#sec005}
--------------------------------------------------------------------------------

Next, we assayed synapsis by monitoring the colocalization of two SC components, HTP-3 and SYP-1 \[[@pgen.1008904.ref006], [@pgen.1008904.ref054]\]. When HTP-3 and SYP-1 colocalize, chromosomes are synapsed while regions of HTP-3 devoid of SYP-1 are unsynapsed (see arrows in [Fig 3A](#pgen.1008904.g003){ref-type="fig"}). We evaluated the percentage of nuclei that had completed synapsis as a function of meiotic progression ([Fig 3B](#pgen.1008904.g003){ref-type="fig"}). In contrast to our analysis of pairing, synapsis in *pch-2*^*E253Q*^ mutants was accelerated, similar to but even more severely than *pch-2*Δ mutants ([Fig 3B](#pgen.1008904.g003){ref-type="fig"} and \[[@pgen.1008904.ref050]\]) (p value \< 0.0001, two-tailed Fisher's exact test): More nuclei had completely synapsed chromosomes when synapsis initiates in zone 3 in *pch-2*^*E253Q*^ mutants than control germlines ([Fig 3B](#pgen.1008904.g003){ref-type="fig"}) (p value \< 0.0001, two-tailed Fisher's exact test). In contrast to *pch-2*Δ mutants, *pch-2*^*E253Q*^ mutants did not exhibit defects in SC disassembly in zone 6 ([Fig 3B](#pgen.1008904.g003){ref-type="fig"} and \[[@pgen.1008904.ref050]\]).

![Synapsis is accelerated in *pch-2*^*E253Q*^ mutants, producing non-homologous synapsis.\
A. Images of meiotic nuclei stained with antibodies against HTP-3 and SYP-1. Color and grey scale images are provided. Arrows indicate unsynapsed chromosomes. B. Timecourse of synapsis in wildtype, *pch-2*^*E253Q*^ and *pch-2*Δ mutant germlines. C. Images of meiotic nuclei stained with antibodies against HTP-3, SYP-1 and HIM-8 in wildtype animals, *pch-2*^*E253Q*^ and *pch-2*Δ mutants. Circled nuclei have undergone non-homologous synapsis. D. Quantification of non-homologous synapsis wildtype animals, *pch-2*^*E253Q*^ and *pch-2*Δ mutants. All error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed Fisher exact tests. A \*\*\* indicates a p value \< 0.0001.](pgen.1008904.g003){#pgen.1008904.g003}

We reasoned that the delay in pairing, combined with the acceleration in synapsis, raised the possibility that these events, which are typically coupled, had been uncoupled. To test this possibility, we evaluated whether non-homologous synapsis occurs in *pch-2*^*E253Q*^ mutants. We stained wildtype, *pch-2*Δ and *pch-2*^*E253Q*^ mutant germlines with antibodies against SC components HTP-3 and SYP-1 to evaluate synapsis and HIM-8 to assess pairing. All nuclei in wildtype animals, *pch-2*Δ, and most nuclei in *pch-2*^*E253Q*^ mutants exhibited homologous synapsis (uncircled nuclei in [Fig 3C](#pgen.1008904.g003){ref-type="fig"}). However, we identified meiotic nuclei in which all chromosomes were synapsed but contained two HIM-8 foci, indicating these chromosomes had synapsed with non-homologous partners (circled nuclei in [Fig 3C](#pgen.1008904.g003){ref-type="fig"}). We also observed non-homologous synapsis when we monitored pairing of autosomes using antibodies against ZIM-2, a protein that binds an autosomal PC \[[@pgen.1008904.ref056]\] ([S1A Fig](#pgen.1008904.s001){ref-type="supplementary-material"}). When we quantified this defect, we detected non-homologous synapsis of X chromosomes in 2.5% of meiotic nuclei ([Fig 3D](#pgen.1008904.g003){ref-type="fig"}) and non-homologous synapsis of Chromosome V in 6% of meiotic nuclei ([S1B Fig](#pgen.1008904.s001){ref-type="supplementary-material"}). Unlike HIM-8 \[[@pgen.1008904.ref055]\], ZIM-2 only stains meiotic chromosomes in a subset of meiotic nuclei \[[@pgen.1008904.ref056]\]. Since fewer nuclei are positive for ZIM-2 than HIM-8 in all germlines, this explains the higher frequency of non-homologous synapsis that involves Chromosome V. *C*. *elegans* have six pairs of homologous chromosomes. Therefore, it's possible that as many as 18% of meiotic nuclei have at least one pair of chromosomes undergoing non-homologous synapsis in *pch-2*^*E253Q*^ mutants. However, it's also formally possible that some nuclei contain multiple pairs of chromosomes that are non-homologously synapsed and that 18% may be an overstatement. Unfortunately, we were unable to directly test this possibility due to technical limitations.

*pch-2*^*E253Q*^ mutants lose crossover assurance {#sec006}
-------------------------------------------------

We then monitored meiotic DNA repair and the formation of crossovers. To assess DNA repair, we monitor the appearance and disappearance of RAD-51 from meiotic chromosomes as a function of meiotic progression ([Fig 4A](#pgen.1008904.g004){ref-type="fig"}). RAD-51 is required for all meiotic DNA repair in *C*. *elegans* \[[@pgen.1008904.ref057]\]. Its appearance on chromosomes signals the formation of double strand breaks (DSBs) that need to be repaired (see zones 3 and 4 in wildtype in [Fig 4B](#pgen.1008904.g004){ref-type="fig"}) and its disappearance indicates the entry of DSBs into a DNA repair pathway (see zones 5 and 6 in wildtype in [Fig 4B](#pgen.1008904.g004){ref-type="fig"}) \[[@pgen.1008904.ref003]\]. The appearance and disappearance of RAD-51 on meiotic chromosomes in *pch-2*^*E253Q*^ mutants was indistinguishable from that in wildtype in zones 1--4. In zone 5, we detected fewer RAD-51 foci, suggesting that meiotic DNA repair may occur slightly more rapidly in *pch-2*^*E253Q*^ mutants (p value \< 0.0001, two-tailed t- test). However, we observed an acceleration in DNA repair much earlier in *pch-2*Δ mutants (see zone 4, [Fig 4B](#pgen.1008904.g004){ref-type="fig"} and \[[@pgen.1008904.ref050]\] (p value \< 0.0001, two-tailed t-test).

![Meiotic DNA repair is not affected in *pch-2*^*E253Q*^ mutants but crossover assurance is.\
A. Images of meiotic nuclei stained with DAPI and antibodies against RAD-51. Color and grey scale images are provided. B. Timecourse of the average number of RAD-51 foci per nucleus in wildtype, *pch-2*^*E253Q*^ and *pch-2*Δ mutant germlines. Error bars indicate 2XSEM. C. Images of meiotic nuclei stained with DAPI and antibodies against GFP. D. Percentage of nuclei with five GFP::COSA-1 foci in wildtype animals, *pch-2*^*E253Q*^ and *pch-2*Δ mutants. Error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed Fisher exact tests. A \*\*\* indicates a p value \< 0.0001.](pgen.1008904.g004){#pgen.1008904.g004}

We assayed crossover formation in *pch-2*^*E253Q*^ mutants by visualizing GFP::COSA-1 foci formation in late meiotic prophase. GFP::COSA-1 cytologically marks putative crossovers and its appearance as robust foci is mechanistically associated with the process of crossover designation \[[@pgen.1008904.ref058]\]. Almost all nuclei in wildtype worms had six GFP::COSA-1 foci per nucleus, one per homolog pair ([Fig 4C](#pgen.1008904.g004){ref-type="fig"}, top, and [4D](#pgen.1008904.g004){ref-type="fig"}) \[[@pgen.1008904.ref058]\]. In contrast, *pch-2*^*E253Q*^ mutants had a greater number of nuclei with five GFP::COSA-1 foci, similar to *pch-2*Δ mutants, indicating a defect in crossover assurance ([Fig 4C](#pgen.1008904.g004){ref-type="fig"}, bottom, [4D](#pgen.1008904.g004){ref-type="fig"} and \[[@pgen.1008904.ref050]\]). Given the *in vitro* behavior of the PCH-2^E253Q^ hexamer \[[@pgen.1008904.ref053]\], this phenotype is likely because inappropriate crossover intermediates are stabilized at the expense of appropriate ones. Alternatively, these meiotic nuclei may result from the non-homologous synapsis we also observe in this mutant background. However, we do not observe a delay in meiotic DNA repair in *pch-2*^*E253Q*^ mutants ([Fig 4B](#pgen.1008904.g004){ref-type="fig"}). Further, *pch-2*^*E253Q*^ mutants do not activate feedback mechanisms, as visualized by the extension of DSB-1 on meiotic chromosomes \[[@pgen.1008904.ref059], [@pgen.1008904.ref060]\] ([S2A and S2B Fig](#pgen.1008904.s002){ref-type="supplementary-material"}). Therefore, we favor the first interpretation.

CMT-1 is required for the synapsis checkpoint {#sec007}
---------------------------------------------

During the spindle checkpoint, PCH-2 requires the presence of an adapter protein, CMT-1 (p31^comet^ in mammalian cells), to bind and remodel a HORMAD protein required for the spindle checkpoint response, Mad2 \[[@pgen.1008904.ref053], [@pgen.1008904.ref061], [@pgen.1008904.ref062]\]. Based on a recent report that the rice ortholog of CMT-1 is an SC component and required for pairing, synapsis and double strand break formation \[[@pgen.1008904.ref063]\], we tested whether *cmt-1* had a role in meiotic prophase by assessing whether it was required for meiotic prophase checkpoints in *C*. *elegans*. We introduced a null mutation of *cmt-1* into *syp-1* mutants. The absence of SC in *syp-1* mutants results in unsynapsed chromosomes, which activate very high levels of germline apoptosis in response to both the synapsis and the DNA damage checkpoints \[[@pgen.1008904.ref064]\] ([Fig 5A](#pgen.1008904.g005){ref-type="fig"}). *cmt-1* single mutants had wildtype levels of apoptosis ([Fig 5B](#pgen.1008904.g005){ref-type="fig"}). In contrast to *syp-1* single mutants, *syp-1;cmt-1* double mutants had intermediate levels of germline apoptosis ([Fig 5B](#pgen.1008904.g005){ref-type="fig"}), indicating that CMT-1 is required for either the synapsis or DNA damage checkpoint. To distinguish between these two checkpoints, we used *syp-1;spo-11* double mutants, which do not generate double strand breaks \[[@pgen.1008904.ref018]\]. As a result, these double mutants do not activate the DNA damage checkpoint ([Fig 5A](#pgen.1008904.g005){ref-type="fig"}) and produced an intermediate level of apoptosis ([Fig 5B](#pgen.1008904.g005){ref-type="fig"}). \[[@pgen.1008904.ref064]\]. When we generate *syp-1;spo-11;cmt-1* triple mutants, we observed wildtype levels of apoptosis, similar to but slightly higher than *cmt-1* single mutants ([Fig 5B](#pgen.1008904.g005){ref-type="fig"}) (p value \< 0.05, two tailed t-test). Therefore, CMT-1 is required to activate apoptosis in response to the synapsis checkpoint, similar to *pch-2*Δ mutants.

![CMT-1 is required for the synapsis checkpoint.\
A. Cartoon of meiotic checkpoint activation in *C*. *elegans*. B. Mutation of *cmt-1* reduces apoptosis in *syp-1* single mutants and *syp-1;spo-11* double mutants. Error bars indicate 2XSEM. C. *pch-2*^*E253Q*^ reduces apoptosis in *syp-1* and *syp-1;spo-11* mutants but not in *syp-1;cmt-1* or *syp-1;spo-11;cmt-1* mutants. Significance was assessed by performing two-tailed t-tests. A \*\*\* indicates a p value \< 0.0001, a \*\* indicates a p value \< 0.01 and an n.s. indicates not significant.](pgen.1008904.g005){#pgen.1008904.g005}

*cmt-1* mutants phenotypically resemble *pch-2*^*E253Q*^ mutants {#sec008}
----------------------------------------------------------------

Based on the requirement for CMT-1 in the synapsis checkpoint, we assessed pairing, synapsis, meiotic DNA repair and crossover formation in *cmt-1* mutants. Similar to our analysis of *pch-2*^*E253Q*^ mutants, pairing was delayed in *syp-1;cmt-1* double mutants (see zone 2, [Fig 6A](#pgen.1008904.g006){ref-type="fig"}) (p value \< 0.0001, two-tailed Fisher's exact test) and synapsis was accelerated in *cmt-1* single mutants (see zone 3, [Fig 6B](#pgen.1008904.g006){ref-type="fig"}) (p value \< 0.0001, two-tailed Fisher's exact test). We also detected non-homologous synapsis at levels similar to that of *pch-2*^*E253Q*^ mutants (Figs [6C](#pgen.1008904.g006){ref-type="fig"}, [6D](#pgen.1008904.g006){ref-type="fig"} and [S1](#pgen.1008904.s001){ref-type="supplementary-material"}). Meiotic DNA repair in *cmt-1* mutants, as visualized by the appearance and disappearance of RAD-51 ([S3A Fig](#pgen.1008904.s003){ref-type="supplementary-material"}), and meiotic progression, as visualized by the appearance and disappearance of a protein required for DSB formation, DSB-1 ([S2A and S2B Fig](#pgen.1008904.s002){ref-type="supplementary-material"}), closely resembled that of wildtype germlines. However, we did observe a delay in RAD-51 removal in *cmt-1* mutants (zones 5 and 6, p value \< 0.0001, two-tailed Fisher's exact test). It is unclear whether this delay is biologically relevant, since we only observe a slight delay in DSB-1 removal ([S2B Fig](#pgen.1008904.s002){ref-type="supplementary-material"}). In addition, crossover assurance was reduced ([S3B Fig](#pgen.1008904.s003){ref-type="supplementary-material"}).

![*cmt-1* mutants delay pairing, accelerate synapsis and exhibit non-homologous synapsis, similar to *pch-2*^*E253Q*^ mutants.\
A. Timecourse of pairing in wildtype and *cmt-1* mutant germlines. B. Timecourse of synapsis in wildtype and *cmt-1* mutant germlines. C. Images of meiotic nuclei stained with antibodies against HTP-3, SYP-1 and HIM-8 in *cmt-1* and *cmt-1;pch-2*Δ mutants. The circled nucleus has undergone non-homologous synapsis. D. Quantification of non-homologous synapsis wildtype animals, *cmt-1*, *cmt-1;pch-2*^*E253Q*^ and *cmt-1;pch-2*Δ mutants. All error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed Fisher exact tests. A \*\*\* indicates a p value \< 0.0001.](pgen.1008904.g006){#pgen.1008904.g006}

The meiotic phenotypes of *cmt-1* mutants are more similar to that of *pch-2*^*E253Q*^ mutants than to that of *pch-2*Δ mutants, suggesting that PCH-2 can bind its meiotic substrates effectively in the absence of CMT-1 but CMT-1 is required for PCH-2's hydrolysis of ATP. This is in contrast to PCH-2's interaction with Mad2, which depends on CMT-1 \[[@pgen.1008904.ref053], [@pgen.1008904.ref061]\]. Consistent with this interpretation, *cmt-1;pch-2^E253Q^* double mutants had a similar frequency of non-homologous synapsis ([Fig 6D](#pgen.1008904.g006){ref-type="fig"}), nuclei with five GFP::COSA-1 foci ([S3B Fig](#pgen.1008904.s003){ref-type="supplementary-material"}), viable offspring and male-self progeny as either single mutant ([Table 1](#pgen.1008904.t001){ref-type="table"}). Finally, *syp-1;pch-2*^*E253Q*^*;cmt-1* and *syp-1;spo-11;pch-2*^*E253Q*^*;cmt-1* mutants did not exhibit any further reduction in germline apoptosis than *syp-1;pch-2*^*E253Q*^ and *syp-1;spo-11;pch-2*^*E253Q*^ mutants ([Fig 5D](#pgen.1008904.g005){ref-type="fig"}) (p values = 0.596 and 0.891, respectively, two-tailed t-tests). Further, since *cmt-1* mutants result in meiotic phenotypes distinct from those we reported for spindle checkpoint mutants \[[@pgen.1008904.ref065]\], specifically non-homologous synapsis, CMT-1's role in meiotic prophase is independent of its regulation of Mad2.

10.1371/journal.pgen.1008904.t001

###### Viability and Him phenotype.

![](pgen.1008904.t001){#pgen.1008904.t001g}

  Genotype                   \% viability (total number of progeny)   \% male self-progeny
  -------------------------- ---------------------------------------- ----------------------
  wildtype                   100% (3949)                              0.05%
  *cmt-1;pch-2^E253Q^*       100% (2349)                              0.34%
  *cmt-1*                    100% (3654)                              0.27%
  *pch-2*^*E253Q*^*;cmt-1*   100% (2721)                              0.25%

Non-homologous synapsis in *cmt-1* mutants relies on PCH-2 {#sec009}
----------------------------------------------------------

We previously showed that CMT-1 is required for PCH-2 to localize to mitotic chromosomes during the spindle checkpoint \[[@pgen.1008904.ref066]\]. We tested whether this was also true during meiotic prophase and found that CMT-1 was dispensable for PCH-2's localization to meiotic chromosomes ([Fig 7A](#pgen.1008904.g007){ref-type="fig"}, grayscale images in [S4 Fig](#pgen.1008904.s004){ref-type="supplementary-material"}). Consistent with CMT-1 being required for PCH-2's hydrolysis of ATP and release of substrates, we observed that PCH-2 stayed on meiotic chromosomes slightly longer than in wildtype germlines ([Fig 7C](#pgen.1008904.g007){ref-type="fig"}).

![PCH-2 localizes to meiotic chromosomes in *cmt-1* mutants.\
A. Whole germline image of PCH-2 and DAPI staining in a *cmt-1* mutant germline. Scale bar indicates 20 microns. B. Meiotic nuclei in mid-pachytene stained with DAPI and antibodies against PCH-2 in *cmt-1* mutants. C. Quantification of percentage of PCH-2-positive nuclei in wildtype and *cmt-1* mutant germlines. Error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed t-tests. A \*\* indicates a p value \< 0.01.](pgen.1008904.g007){#pgen.1008904.g007}

During mitotic divisions in the *C*. *elegans* embryo, loss of CMT-1 partially suppresses the spindle checkpoint defect observed in *pch-2* mutants \[[@pgen.1008904.ref066]\]. Since PCH-2 ensures availability of the inactive conformer of Mad2 so that it can be converted to the active one during checkpoint activation \[[@pgen.1008904.ref067], [@pgen.1008904.ref068]\], we hypothesize that this genetic interaction results because loss of CMT-1 makes more inactive Mad2 available. In this way, PCH-2 and CMT-1 would control the spindle checkpoint by regulating available, soluble pools of inactive and active Mad2. We wondered if there was a similar relationship between PCH-2 and CMT-1 in meiotic prophase. To test this, we generated *cmt-1;pch-2Δ* double mutants and assayed non-homologous synapsis. Unlike *cmt-1* single mutants and similar to *pch-2*Δ mutants, we did not detect non-homologous synapsis in *cmt-1;pch-2Δ* double mutants ([Fig 6C and 6D](#pgen.1008904.g006){ref-type="fig"}). Thus, PCH-2 is epistatic to CMT-1 during meiosis, at least in the context of non-homologous synapsis, supporting our interpretation that PCH-2 can bind its meiotic substrates independent of CMT-1 and suggesting that some of PCH-2's regulation of its meiotic substrates occurs directly on chromosomes.

Discussion {#sec010}
==========

*In vitro*, PCH-2^E253Q^ protein binds ATP and its spindle checkpoint substrate, Mad2, but fails to remodel it, due to an inability to hydrolyze ATP \[[@pgen.1008904.ref053]\]. Here, we show that the meiotic phenotypes observed in *pch-2*^*E253Q*^ mutants are consistent with a role for PCH-2 in disassembling inappropriate pairing, synapsis and crossover recombination intermediates in *C*. *elegans*, resulting in non-homologous synapsis (Figs [3C](#pgen.1008904.g003){ref-type="fig"}, [3D](#pgen.1008904.g003){ref-type="fig"} and [S1](#pgen.1008904.s001){ref-type="supplementary-material"}) and a loss of crossover assurance ([Fig 4D](#pgen.1008904.g004){ref-type="fig"}). The effect we observe on these meiotic prophase events seems limited, affecting a small proportion of nuclei, but this may reflect either the inherent fidelity of these processes or the existence of redundant mechanisms that contribute to fidelity in *C*. *elegans*. Further, a role for PCH-2 in proofreading may be more apparent in organisms or situations in which homolog interactions are more challenging. Indeed, PCH-2's involvement in the interchromosomal effect in *Drosophila* \[[@pgen.1008904.ref069]\], in which chromosome rearrangements affect crossover control on other chromosomes, supports this possibility. Nevertheless, our results demonstrate that PCH-2 proofreads interactions between homologous chromosomes to ensure that they are correct.

We previously showed that PCH-2 decelerates homolog pairing, synapsis and recombination, coordinating these meiotic prophase events \[[@pgen.1008904.ref050]\]. Here, we argue that PCH-2 acts directly on chromosomes to proofread meiotic interhomolog interactions and ensure their fidelity. This role is supported by several pieces of data. First, PCH-2 localizes to meiotic chromosomes, both before and after synapsis \[[@pgen.1008904.ref050]\]. This localization is functional, as demonstrated by its persistence on the synaptonemal complex and correlation with an extension of homolog access in mutants defective in recombination \[[@pgen.1008904.ref050], [@pgen.1008904.ref070]\]. Second, despite the defects we report, *pch-2*Δ, *pch-2*^*E253Q*^ and *cmt-1* mutants do not show acceleration of meiotic progression, as assayed by SUN-1 phosphorylation \[[@pgen.1008904.ref050]\], appearance of transition zone nuclei (Figs [1](#pgen.1008904.g001){ref-type="fig"} and [7](#pgen.1008904.g007){ref-type="fig"} and \[[@pgen.1008904.ref050]\]), ZIM-2 ([S1 Fig](#pgen.1008904.s001){ref-type="supplementary-material"}) or DSB-1 localization ([S2 Fig](#pgen.1008904.s002){ref-type="supplementary-material"}), indicating that PCH-2 and CMT-1 do not coordinate these meiotic prophase events indirectly through misregulation of meiotic progression. Finally, meiotic defects associated with loss of CMT-1 rely on PCH-2 function ([Fig 6D](#pgen.1008904.g006){ref-type="fig"}), unlike what we observe in mitosis \[[@pgen.1008904.ref066]\]. In mitosis, CMT-1 is epistatic to PCH-2, which we attribute to misregulation of soluble pools of Mad2. Soluble pools of at least one meiotic HORMAD, HTP-1, have been implicated in ensuring both accurate homolog synapsis and proper meiotic progression \[[@pgen.1008904.ref023]\]. If PCH-2 and CMT-1 were regulating homolog pairing, synapsis and recombination via control of meiotic progression, we might predict that CMT-1 would be epistatic to PCH-2 in meiosis, as it is in mitosis. Taken together, these data favor a model in which PCH-2 and CMT-1 proofread interactions between homologous chromosomes that underlie pairing, synapsis and recombination in *C*. *elegans*. Since pairing, synapsis and recombination depend on meiotic HORMADs adopting their closed conformations \[[@pgen.1008904.ref045]\], we hypothesize that these interactions between homologous chromosomes either involve or are stabilized by closed versions of meiotic HORMADs and PCH-2, in collaboration with CMT-1, remodels them to disassemble or destabilize them. In systems such as plants, yeast and mice, we propose that PCH-2 plays a similar role in addition to removing or relocalizing meiotic HORMADs to signal meiotic progression \[[@pgen.1008904.ref028], [@pgen.1008904.ref030]--[@pgen.1008904.ref032]\].

We were surprised to see that PCH-2 localized to meiotic chromosomes in *cmt-1* mutants ([Fig 7](#pgen.1008904.g007){ref-type="fig"}), unlike what we observe during the spindle checkpoint response \[[@pgen.1008904.ref066]\], and that *cmt-1* mutants closely resembled *pch-2*^*E253Q*^ mutants in exhibiting non-homologous synapsis and a loss of crossover assurance (Figs [6](#pgen.1008904.g006){ref-type="fig"} and [S2](#pgen.1008904.s002){ref-type="supplementary-material"}). Since PCH-2's localization to meiotic chromosomes depends on synapsis \[[@pgen.1008904.ref050]\], this localization may not accurately represent interaction with its proposed meiotic substrates, meiotic HORMADs. Alternatively, these data may suggest that PCH-2 is competent to bind meiotic HORMADs in the absence of CMT-1 and that CMT-1's meiotic function is to promote PCH-2's ATPase activity and ability to remodel these substrates. This is unlike its role in the spindle checkpoint, in which CMT-1/p31^comet^ is essential for PCH-2 to bind its substrate, Mad2 \[[@pgen.1008904.ref053], [@pgen.1008904.ref061], [@pgen.1008904.ref062], [@pgen.1008904.ref071]\]. This difference raises the possibility that the interaction between PCH-2 and meiotic HORMADs during their remodeling is substantially different than that with Mad2. This hypothesis is supported by the findings that budding yeast, in which *PCH2* was originally identified \[[@pgen.1008904.ref072]\], does not appear to have a CMT-1/p31^comet^ ortholog \[[@pgen.1008904.ref073], [@pgen.1008904.ref074]\] and budding yeast Pch2 can directly interact with and remodel the budding yeast meiotic HORMAD, Hop1, *in vitro* \[[@pgen.1008904.ref029]\]. However, another possibility is that PCH-2's ability to remodel meiotic HORMADs exists in two modes: 1) a mode that proofreads meiotic interhomolog interactions during pairing, synapsis and recombination and depends on CMT-1 for ATP hydrolysis, but not substrate binding; and 2) one that removes meiotic HORMADs during meiotic progression which relies on CMT-1 for both substrate recognition and ATP hydrolysis. Such a model raises the immediate question of how these two modes might be regulated in an organism with both.

The PCH-2/HORMAD genetic module is evolutionarily ancient \[[@pgen.1008904.ref075], [@pgen.1008904.ref076]\], having been identified as operons in several bacteria \[[@pgen.1008904.ref077]\], suggesting that this pair of proteins has been co-opted to function in multiple molecular contexts. While we can easily detect an interaction between PCH-2 and CMT-1, and CMT-1 and Mad2, by two-hybrid experiments \[[@pgen.1008904.ref066]\], we have not been able to observe a similar interaction between PCH-2 or CMT-1 and any of the four meiotic HORMADs present in *C*. *elegans*, HTP-3, HIM-3, HTP-1 and HTP-2, making it difficult to identify what regions of these proteins are required to interact with PCH-2. Genetic mutations, combined with cytological analysis, seems the most straightforward way, at least in *C*. *elegans*, to understand whether and how PCH-2 and meiotic HORMADs interact to regulate meiotic pairing, synapsis and recombination.

Materials and Methods {#sec011}
=====================

Genetics and worm strains {#sec012}
-------------------------

The *C*. *elegans* Bristol N2 \[[@pgen.1008904.ref078]\] was used as the wild-type strain. All strains were maintained at 20°C under standard conditions unless otherwise stated. Mutations and rearrangements used were as follows:

1.  LG I: *cmt-1(ok2879)*

2.  LG II: *pch-2(blt5)*, *meIs8 \[Ppie-1*::*GFP*::*cosa-1 + unc-119(+)\]*

3.  LG IV: *spo-11(ok79)*, *nT1\[unc-*?*(n754) let-*?*(m435)\] (IV*, *V)*, *nTI \[qIs51\]*

4.  LG V: *syp-1(me17)*, *bcIs39 \[lim-7p*::*ced-1*::*GFP + lin-15(+)\]*

The *pch-2(blt5)* allele, referred to as *pch-2*^*E253Q*^, was created by CRISPR-mediated genomic editing as described in \[[@pgen.1008904.ref051], [@pgen.1008904.ref052]\]. pDD162 was mutagenized using Q5 mutagenesis (New England Biolabs) and oligos GTTTTTGTTCTTATCGACGGTTTTAGAGCTAGAAATAGCAAGT and CAAGACATCTCGCAATAGG. The resulting plasmid was sequenced and two different correct clones (50ng/ul total) were mixed with pRF4 (100ng/ul) and the repair oligo CTCGTTCAAAAAATGTTCGATCAAATTGATGAACTAGCTGAAGATGAGAAGTGCATGGTTTTTGTGCTCATCGACCAAGTTTGATTTTTTTAAAAAACAATTTTTCTGGTTTTCATCAGTTTTTATGTCAGGTTGAAT (30ng/ul). Wildtype worms were picked as L4s, allowed to age 15--20 hours at 20°C and injected with the described mix. Worms that produced rolling progeny were identified and F1 rollers, as well as their wildtype siblings, were placed on plates seeded with OP50, 1--2 rollers per plate and 6--8 non-rolling siblings per plate, and allowed to produce progeny. PCR and Bsp1286I digestions were performed on these F1s to identify worms that contained the mutant allele and individual F2s were picked to identify mutant homozygotes. Multiple homozygotes carrying the *pch-2(blt5)* mutant allele were backcrossed against wildtype worms at least three times and analyzed to determine whether they produced the same mutant phenotype.

Antibodies, Immunostaining and Microscopy {#sec013}
-----------------------------------------

DAPI staining and immunostaining was performed as in \[[@pgen.1008904.ref064]\] 20 to 24 hours post L4 stage. Primary antibodies were as follows (dilutions are indicated in parentheses): rabbit anti-PCH-2 (1∶500) \[[@pgen.1008904.ref050]\], rabbit anti-SYP-1 (1:500) \[[@pgen.1008904.ref006]\], chicken anti-HTP-3 (1:250) \[[@pgen.1008904.ref054]\], guinea pig anti-HTP-3 (1:250) \[[@pgen.1008904.ref054]\], rabbit anti-ZIM-1 (1:1000), guinea pig anti-ZIM-2 (1:2500) \[[@pgen.1008904.ref056]\], guinea pig anti-HIM-8 (1:250) \[[@pgen.1008904.ref055]\], mouse anti-GFP (1:100) (Invitrogen), guinea pig anti-DSB-1 (1:500) \[[@pgen.1008904.ref060]\] and rabbit anti-RAD-51 (1:1000) (Novus Biologicals). Secondary antibodies were Cy3 anti-rabbit, anti-guinea pig and anti-chicken (Jackson Immunochemicals) and Alexa-Fluor 488 anti-guinea pig and anti-rabbit (Invitrogen). All secondary antibodies were used at a dilution of 1:500.

All images were acquired using a DeltaVision Personal DV system (Applied Precision) equipped with a 100X N.A. 1.40 oil-immersion objective (Olympus), resulting in an effective XY pixel spacing of 0.064 or 0.040 μm. Three-dimensional image stacks were collected at 0.2-μm Z-spacing and processed by constrained, iterative deconvolution. Image scaling and analysis were performed using functions in the softWoRx software package. Projections were calculated by a maximum intensity algorithm. Composite images were assembled and some false coloring was performed with Adobe Photoshop.

Scoring of germline apoptosis was performed as previously described in \[[@pgen.1008904.ref064]\] in strains containing *bcIs39 \[lim-7p*::*ced-1*::*GFP + lin-15(+)\]* with the following exceptions. L4 hermaphrodites were allowed to age for 22 hours. They were then mounted under coverslips on 1.5% agarose pads containing 0.2mM levamisole and scored. A minimum of twenty-five germlines was analyzed for each genotype.

Quantification of pairing, synapsis, RAD-51 foci, GFP::COSA-1 foci, and DSB-1 positive nuclei was performed on animals 24 hours post L4 stage and with a minimum of three germlines per genotype. Relevant statistical analysis, as indicated in the Figure Legends, was used to assess significance. The number of nuclei assayed for each genotype for all figures is shown in [S1 Table](#pgen.1008904.s005){ref-type="supplementary-material"}.

Supporting information {#sec014}
======================

###### Autosomes undergo non-homologous synapsis in *pch-2*^*E253Q*^ and *cmt-1* mutants.

A. Images of meiotic nuclei stained with antibodies against HTP-3, SYP-1 and ZIM-2 in wildtype animals, *pch-2*^*E253Q*^ and *cmt-1* mutants. Circled nuclei have undergone non-homologous synapsis. B. Quantification of non-homologous synapsis wildtype animals, *pch-2*^*E253Q*^ and *cmt-1* mutants. Error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed Fisher exact tests. A \*\*\* indicates a p value \< 0.0001.

(TIF)

###### 

Click here for additional data file.

###### Meiotic progression is unaffected in *pch-2*^*E253Q*^ and *cmt-1* mutants.

A. Whole germline images of DSB-1 and DAPI staining in a wildtype, *pch-2*^*E253Q*^ and *cmt-1* mutant germline. Scale bar indicates 20 microns. B. Quantification of percentage of DSB-1-positive nuclei in wildtype, *pch-2*^*E253Q*^ and *cmt-1* mutant germlines. Error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed t-tests. A \* indicates a p value \< 0.05 and an n.s. indicates not significant.

(TIF)

###### 

Click here for additional data file.

###### Meiotic DNA repair is not affected in *cmt-1* mutants but crossover assurance is, similar to *pch-2*^*E253Q*^ mutants.

A. Timecourse of the average number of RAD-51 foci per nucleus in wildtype and *cmt-1* mutant germlines. Error bars indicate 2XSEM. B. Percentage of nuclei with five GFP::COSA-1 foci in wildtype animals, *cmt-1* single and *cmt-1;pch-2*^*E253Q*^ double mutants. Error bars indicate 95% confidence intervals. Significance was assessed by performing two-tailed Fisher exact tests. A \*\*\* indicates a p value \< 0.0001.

(TIF)

###### 

Click here for additional data file.

###### Grayscale images of PCH-2 antibody staining in wildtype animals, *pch-2*^*E253Q*^ and *cmt-1* mutants.

A. Whole germline images. Scale bar indicates 20 microns. B. Meiotic nuclei in mid-pachytene. C. Meiotic nuclei in late pachytene.

(TIF)

###### 

Click here for additional data file.

###### Number of nuclei assayed for each genotype for all figures.

(DOCX)

###### 

Click here for additional data file.
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Dear Dr Bhalla,

Thank you very much for submitting your Research Article entitled \'PCH-2 collaborates with CMT-1 to proofread meiotic homolog interactions.\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. Based on the reviews, we encourage you to include a more detailed quantification and analysis of both the pairing defects of the autosomes as well as the non-homologous synapsis, occurring in the mutants described in this manuscript. Some of these experiments were stated as data not shown in the manuscript but this data should be included in the manuscript figures.  We encourage you to pay particular attention to the excellent suggestions from Reviewers 2 and 3 to carry out these experiments.  Further, all three reviewers requested that the existing and additional pairing and non-homologous synapsis quantifications include the inclusion of specific mutants, such as cmt-1 and cmt-1; pch-2E253Q.  Importantly, statistics and n-values for all of your experiments should be included throughout the manuscript.  As mentioned by Reviewers 1 and 2, please consider revising the use of "proofreading" for describing the role of PCH-2.  We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Diana E. Libuda, Ph.D.

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: In the manuscript by Giacopazzi, Vong et al, the authors characterize the in vivo phenotypes of a mutant in PCH-2 (pch-2E253Q). In vitro characterization previously showed that this mutant could bind its substrate but could not hydrolyze ATP. They find that pch-2E253Q mutants localize PCH-2E253Q but have a delay in pairing, accelerate synapsis, have a small fraction of non-homologous synapsis, and lose crossover assurance. The phenotype of non-homologous synapsis was different in the pch-2E253Q than in the pch-2 mutants, suggesting that the pch-2E253Q mutant is trapping an intermediate. They then ask if CMT-1 is needed for these events. They find that the phenotypes of cmt-1 mutants are similar to that of pch-2E253Q mutants, with a delay in pairing, accelerated synapsis, non-homologous synapsis, and reduced crossover assurance.

This manuscript details interesting results to test their hypothesis that they can reveal intermediates with the pch-2E253Q mutants and that the adaptor CMT-1 is not required for binding substrates but is required to remodel them. However, there are some further questions that need to be addressed:

1\) In Figure 2C, the authors are arguing that they can trap the pairing intermediates in pch-2E253Q mutants. It would be more convincing if they directly show the difference between pch-2delta and pch-2E253Q, along with wildtype.

2\) Similarly, the comparison of HIM-8 foci in pch-2E253Q and pch-2delta is needed to show that this is a defect specific to trapping intermediates.

3\) What is the range of numbers and percent of each of GFP::COSA-1 foci? Having this range will help understand the severity of the defect.

4\) Is there an increase in chromosome mis-segregation in the pch-2E253Q mutants, or less viable offspring?

5\) Does the role of CMT-1 in activating apoptosis require PCH-2 and ATP hydrolysis? In the pch-2E253Q mutant, what are the levels of apoptosis and does the mutant decrease apoptosis in syp-1 mutants, like cmt-1 mutants do?

6\) To be sure that CMT-1 and PCH-2 are acting together to disrupt non-homologous synapsis, the cmt-1; pch-2E253Q double mutant experiment should be performed to see if there is an additive effect or not.

7\) I am struggling with the role of PCH-2 in proofreading versus a cell-cycle regulator needed to couple pairing and synapsis. I am wondering if the authors can discuss these differences further and focus on why they are suggesting proofreading?

Minor issues:

1\) When referring to yeast proteins and genes, the yeast terminology should be used. Pch2 = protein, PCH2 = gene

2\) In line 229-231, the authors conclude that PCH-2 can bind the meiotic substrates in the absence of CMT-1, but they do not show that until later. I found this statement confusing.

3\) Line 149 get rid of comma after "in contrast"

4\) Line 277-278 unneeded "localized".

Reviewer \#2: Review attached

Reviewer \#3: The manuscript by Giacopazzi et al., provides insight into the role of the enigmatic AAA-ATPase PCH-2 in ensuring faithful meiotic prophase events. Taking advantage of a mutation in the conserved Walker B motif that is able to bind ATP but no hydrolyze it, the authors monitor localization, pairing, synapsis, and meiotic recombination progression. They find that pch-2E235Q has delayed pairing (of the X chromosome), faster SC formation leading to some nonhomologous synapsis, and relatively normal RAD-51 kinetics, but a slight reduction in the frequency of COSA-1 foci, suggesting a problem with crossover assurance. Most of these phenotypes are also observed in the p31comet ortholog, CMT-1; however, unlike its role in the spindle assembly checkpoint, CMT-1 is not required to localize PCH-2 to meiotic chromosomes. Together these results suggest that CMT-1 plays a distinct role in monitoring meiotic prophase events versus its canonical role in the spindle assembly checkpoint pathway. There are some interesting data presented, although not much insight into the underlying mechanism. In many figures, there are no statistics. Further, including the pch-2 null mutant in the analysis and reorganizing the figures would make it easier to compare pch-2 null, pch-2E235Q and cmt-1.

Abstract: "In vitro, this mutant binds its substrates . . ." -- to my knowledge this has only been demonstrated for MAD-2 in the spindle assembly checkpoint and not for potential meiotic substrates (Ye, et al., 2015). This should be changed to reflect this. Further on line 29 in the abstract, please change "indicate" to "suggest" as no direct binding of meiotic substrates is shown in this manuscript.

I recommend that the data for the cmt-1 mutant be incorporated into the figures for the pch-2E235Q as indicated below.

Figure 1: Please indicate that this is antibody staining. There is significantly more background/non-nuclear staining in the mutant compared to wild type. Is this consistent over different experiments? Either replace the figure or suggest why it appears different. Please add the PCH-2 staining in cmt-1 mutant to this figure instead of figure 7.

Figure 2: As the X chromosome has different properties compared to the autosomes, it would be nice to include analysis of pairing of an autosome. Please also add the analysis of pairing of the pch-2 null and cmt-1 mutants in this figure (Fig 6A). Statistics should also be included.

Figure 3: Please quantify the extent of non-homologous synapsis. The data for ZIM-1 and ZIM-2 should be included, as well as the data for pch-2 null and cmt-1 mutants (Figure 6B).

Figure 4: Please add the pch-2 null and cmt-1 data from Supplemental Figure 2 here as well as statistics.

Minor: Several times throughout the manuscript meiotic DNA repair is written (line 98, line172, and others), I think is should be DSB. There is also a typo on line 278.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: None

Reviewer \#2: Yes

Reviewer \#3: No: The authors include \"data not shown\" - this is also indicated in my comments to the authors.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

###### 

Submitted filename: Giacopazzi_Vong_PlosGenetics.docx

###### 

Click here for additional data file.

10.1371/journal.pgen.1008904.r002
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###### 

Submitted filename: coverletter.doc

###### 

Click here for additional data file.
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1 Jun 2020

Dear Dr Bhalla,

We are pleased to inform you that your manuscript entitled \"PCH-2 collaborates with CMT-1 to proofread meiotic homolog interactions.\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Diana E. Libuda, Ph.D.

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

The reviewers all agree the manuscript is ready to be accepted, but given that Reviewer \#2 noted a desire for more extensive analysis of non-homologous synapsis and Reviewer \#3 requested a specific wording change in the abstract with regards to the extensiveness of the defects on both non-homologous synapsis and crossover assurance, the author must make the Reviewer \#3 requested wording change in the abstract prior to publication.  In addition, the authors should make the Reviewer \#2 requested changes to the supplemental figures.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**
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